CorMedix announces new data at ASN Kidney Week 2024

CorMedix (CRMD) announced new hospital admission and health economic data presented at the American Society of Nephrology Kidney Week 2024 in San Diego, CA from October 24 – 27. This retrospective analysis, using data from the Premier Healthcare Database, evaluated hospital admissions from 2020 to 2022 to examine the demographics, clinical characteristics, and outcomes of adult HD-CVC patients hospitalized for bloodstream infections. Key findings include: The patient population was 58.2% white, 27.1% black, and 56.6% male, with 59.3% aged 60 years or older. The median length of stay for BSI-related hospitalizations was 16 days, with 53.8% of admissions involving time in the ICU. The study reported an all-cause in-hospital mortality rate of 10.3%. Patients had extensive comorbidities, with 87.8% having three or more Charlson comorbidity conditions, and 42.6% had six or more. The median total cost of admission was $157,000, with $65,000 attributed to ICU care alone. Healthcare utilization, including readmissions, placed a significant financial burden resulting from these infections.